In primary metastatic breast cancer (stage C), the mean 5-year OS rate for HER2+ breast cancer in this analysis ranged from 49.0% to 53.0%, which is comparable to the median OS rate for HER2+ breast cancer patients in the literature [29]. This evidence concerns the gene ERBB2 and breast carcinoma.